S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Denali Therapeutics Stock Price, News & Analysis (NASDAQ:DNLI)

$18.37
-0.37 (-1.97%)
(As of 12/8/2023 ET)
Compare
Today's Range
$18.01
$18.72
50-Day Range
$16.20
$21.83
52-Week Range
$15.45
$33.31
Volume
800,496 shs
Average Volume
742,418 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Denali Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.2% Upside
$50.00 Price Target
Short Interest
Bearish
8.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.37mentions of Denali Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$105,641 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.01) to ($2.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

276th out of 954 stocks

Biological Products, Except Diagnostic Industry

32nd out of 129 stocks


DNLI stock logo

About Denali Therapeutics Stock (NASDAQ:DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Stock Price History

DNLI Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Denali Therapeutics Inc DNLI
Denali Therapeutics (DNLI) Receives a New Rating from B.Riley Financial
Jefferies Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
447
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$50.00
High Stock Price Target
$105.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+172.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-325,990,000.00
Pretax Margin
-36.51%

Debt

Sales & Book Value

Annual Sales
$340.81 million
Book Value
$7.68 per share

Miscellaneous

Free Float
127,279,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
1.11

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Ryan J. Watts Ph.D. (Age 47)
    Co-Founder, President, CEO & Director
    Comp: $1.04M
  • Dr. Alexander O. Schuth M.D.Dr. Alexander O. Schuth M.D. (Age 50)
    Co-Founder, CFO, COO & Secretary
    Comp: $737.2k
  • Dr. Marc Tessier-Lavigne Ph.D. (Age 63)
    Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $58.23k
  • Dr. Carole Ho M.D. (Age 50)
    Chief Medical Officer & Head of Development
    Comp: $737.2k
  • Mr. Tyler M. Nielsen (Age 45)
    Senior Vice President of Corporate Finance
  • Dr. Dana Andersen
    Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock Ph.D.
    Chief Scientific Officer
  • Dr. Laura Hansen
    Vice President of Investor Relations
  • Mr. Chris Walsh
    General Counsel
  • Mr. Mark Rowen
    Vice President of Corporate Development














DNLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price target for 2024?

10 analysts have issued 1 year price targets for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $105.00. On average, they predict the company's share price to reach $50.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2023?

Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have decreased by 33.9% and is now trading at $18.37.
View the best growth stocks for 2023 here
.

Are investors shorting Denali Therapeutics?

Denali Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 9,560,000 shares, a decrease of 10.9% from the October 31st total of 10,730,000 shares. Based on an average daily trading volume, of 854,200 shares, the days-to-cover ratio is currently 11.2 days. Approximately 8.4% of the company's shares are short sold.
View Denali Therapeutics' Short Interest
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.09. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $11.16 million. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 11.54%. The firm's revenue for the quarter was down 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.84) earnings per share.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.62%), Wellington Management Group LLP (5.27%), Bank of New York Mellon Corp (1.43%), Federated Hermes Inc. (0.98%), Northern Trust Corp (0.81%) and FMR LLC (0.77%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DNLI) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -